ArticleJournal of medical biochemistry2019
Biochemical Markers for Prediction of Hypertensive Disorders of Pregnancy.
Article in Journal of medical biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Differential impacts of pregnancy-induced hypertension and chronic hypertension on maternal and foetal health outcomes: a systematic review of outcomes and risk factors.Archives of gynecology and obstetrics · 2026Pooled it
- Efficiency of afamin and fibroblast growth factor 21 for early prediction of gestational diabetes mellitus.Scientific reports · 2026Article
- Altered PAPP-A and Placental Thickness in Pre-Eclampsia and Intrauterine Growth Restriction: A Pilot Study.Journal of clinical medicine · 2026Article
- Evaluating an Early Risk Model for Uncomplicated Hypertension in Pregnancy Based on Nighttime Blood Pressure, Uric Acid, and Angiogenesis-Related Factors.International journal of molecular sciences · 2025Article
- Routine ante-natal screening using maternal risk factors and biomarkers for preeclampsia in 11-13Journal of family medicine and primary care · 2024Article
- Early Trimester Maternal Serum β-hCG and PAPP-A Levels as Predictor of Hypertensive disorders of Pregnancy.Journal of obstetrics and gynaecology of India · 2024Article
- Identification and validation of feature genes associated with M1 macrophages in preeclampsia.Aging · 2023Article
- Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia.ACS omega · 2023Article
- Role of First Trimester Screening Biochemical Markers to Predict Hypertensive Pregnancy Disorders and SGA Neonates-A Narrative Review.Healthcare (Basel, Switzerland) · 2023Review
- Serum estradiol to testosterone ratio as a novel predictor of severe preeclampsia in the first trimester.Journal of clinical hypertension (Greenwich, Conn.) · 2023Article
- Analysis of a circRNA-, miRNA-, and mRNA-associated ceRNA network reveals potential biomarkers in preeclampsia a ceRNA network in preeclampsia.Annals of medicine · 2021Article
- Efficacy of aspirin combined with labetalol on gestational hypertension and effect on serum PAPP-A, APN and HMGB1.American journal of translational research · 2021Article
- Integrative analysis provides multi-omics evidence for the pathogenesis of placenta percreta.Journal of cellular and molecular medicine · 2020Article
- Influence of selenium supplementation on carbohydrate metabolism and oxidative stress in pregnant women with gestational diabetes mellitus.Journal of medical biochemistry · 2020Article
- Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in Serbian population.Journal of medical biochemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGestational hypertension (GH) and pre eclampsia (PE) are the most common gestational complications. Several placental biochemical markers are used to predict GH/PE, but with conflicting results.
methodsThe study aim was to estimate the biochemical markers' ability to predict hypertensive disorders in pregnancy. On the first ultrasonographic examination, 104 healthy pregnant women were recruited. At the regular pregnancy check-ups, BMI, blood pressure, occurrence of gestational hypertension (early or late onset), preeclampsia, eclampsia and other complications were recorded. Serum concentrations (in multiples of median - MoM) of human chorionic gonadotropin (HCG) and pregnancyassociated plasma protein A (PAPPA) were measured from the 11th to 14th gestational week, while HCG, alpha feto protein (AFP), estriol and inhibin were determined between the 16th and 19th gestational week.
resultsHypertensive disorders throughout pregnancy were diagnosed in 20.2% women. Early-onset GH was registered in 7 and PE in 6 patients, while 14 had late-onset GH and 10 additional women PE. There were no significant differences (p≥0.05) in biochemical markers concentrations between women with and without GH/PE. PAPPA levels in the first and HCG in the second trimester correlated with early and late GH/PE. Moreover, higher AFP concentrations were registered in women with preeclampsia signs/symptoms. According to ROC analysis, AFP>1.05 MoM properly identified 80% of GH/PE cases. Obtained models imply that HCG, PAPPA and AFP should be used for GH/PE prediction.
conclusionsBiochemical markers HCG, PAPPA and AFP could be useful in predicting gestational hypertension and preeclampsia. However, different markers should be used for early and late onset GH/PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.